# Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC

> **NCT07711470** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 140 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Sugemalimab and Chemotherapy
- **DRUG:** Nab-paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT07711470
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711470, "Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*